Gilead Sciences (NASDAQ:GILD) Rating Lowered to Sell at BidaskClub

Gilead Sciences (NASDAQ:GILD) was downgraded by investment analysts at BidaskClub from a “hold” rating to a “sell” rating in a report released on Tuesday, January 9th.

Several other research firms have also issued reports on GILD. BMO Capital Markets restated a “hold” rating and set a $82.00 price target on shares of Gilead Sciences in a research report on Friday, October 20th. JPMorgan Chase & Co. set a $85.00 price target on shares of Gilead Sciences and gave the company a “buy” rating in a research report on Wednesday, October 25th. Morgan Stanley restated an “equal weight” rating and set a $83.00 price target (up from $77.00) on shares of Gilead Sciences in a research report on Friday, October 6th. ValuEngine lowered shares of Gilead Sciences from a “strong-buy” rating to a “buy” rating in a report on Wednesday, September 13th. Finally, Bank of America dropped their target price on shares of Gilead Sciences from $87.00 to $86.00 and set a “neutral” rating for the company in a report on Wednesday, October 4th. One investment analyst has rated the stock with a sell rating, thirteen have given a hold rating and eighteen have given a buy rating to the company. Gilead Sciences currently has a consensus rating of “Buy” and a consensus target price of $85.53.

Gilead Sciences (NASDAQ:GILD) traded down $0.19 on Tuesday, reaching $80.98. The company had a trading volume of 6,970,543 shares, compared to its average volume of 8,120,000. The company has a current ratio of 3.68, a quick ratio of 3.56 and a debt-to-equity ratio of 1.10. Gilead Sciences has a 1-year low of $63.76 and a 1-year high of $86.27. The company has a market capitalization of $105,510.00, a PE ratio of 9.21, a PEG ratio of -1.76 and a beta of 1.13.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $2.27 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.13 by $0.14. Gilead Sciences had a net margin of 42.22% and a return on equity of 57.15%. The business had revenue of $6.51 billion during the quarter, compared to analyst estimates of $6.40 billion. During the same period in the prior year, the business posted $2.75 earnings per share. The company’s revenue was down 13.2% on a year-over-year basis. equities research analysts predict that Gilead Sciences will post 8.53 EPS for the current year.

In related news, EVP Gregg H. Alton sold 15,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 1st. The shares were sold at an average price of $74.82, for a total value of $1,122,300.00. Following the sale, the executive vice president now owns 77,363 shares in the company, valued at $5,788,299.66. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider John C. Martin sold 73,333 shares of the firm’s stock in a transaction that occurred on Wednesday, November 1st. The stock was sold at an average price of $75.13, for a total transaction of $5,509,508.29. Following the completion of the sale, the insider now owns 3,070,099 shares in the company, valued at approximately $230,656,537.87. The disclosure for this sale can be found here. Insiders sold 591,666 shares of company stock worth $44,466,567 in the last 90 days. 1.30% of the stock is currently owned by corporate insiders.

Several institutional investors have recently modified their holdings of GILD. Notis McConarty Edward boosted its stake in shares of Gilead Sciences by 17.1% during the 1st quarter. Notis McConarty Edward now owns 16,682 shares of the biopharmaceutical company’s stock worth $1,133,000 after acquiring an additional 2,435 shares during the last quarter. Gardiner Nancy B boosted its stake in shares of Gilead Sciences by 8.8% during the 1st quarter. Gardiner Nancy B now owns 4,690 shares of the biopharmaceutical company’s stock worth $319,000 after acquiring an additional 381 shares during the last quarter. Broderick Brian C boosted its stake in shares of Gilead Sciences by 8.5% during the 1st quarter. Broderick Brian C now owns 16,803 shares of the biopharmaceutical company’s stock worth $1,141,000 after acquiring an additional 1,320 shares during the last quarter. Lowe Brockenbrough & Co. Inc. boosted its stake in shares of Gilead Sciences by 0.3% during the 1st quarter. Lowe Brockenbrough & Co. Inc. now owns 19,455 shares of the biopharmaceutical company’s stock worth $1,321,000 after acquiring an additional 60 shares during the last quarter. Finally, Bank of Nova Scotia boosted its stake in shares of Gilead Sciences by 344.4% during the 1st quarter. Bank of Nova Scotia now owns 306,114 shares of the biopharmaceutical company’s stock worth $20,791,000 after acquiring an additional 237,236 shares during the last quarter. Institutional investors and hedge funds own 75.95% of the company’s stock.

WARNING: This story was originally reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this story on another website, it was stolen and republished in violation of United States & international copyright and trademark law. The legal version of this story can be read at https://ledgergazette.com/2018/01/20/gilead-sciences-gild-downgraded-by-bidaskclub-to-sell.html.

About Gilead Sciences

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Analyst Recommendations for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply